Appili Therapeutics Inc.
APLIF
$0.0218
$0.00020.93%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -77.99% | -98.65% | -- | -96.48% | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -77.99% | -98.65% | -- | -96.48% | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -77.99% | -98.65% | -- | -96.48% | -- |
| SG&A Expenses | -30.05% | -19.02% | -24.90% | -23.81% | -58.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -12.00% | 46.32% | 22.54% | -5.07% | -1.28% |
| Operating Income | -4.44% | -79.29% | -22.54% | -8.62% | 20.97% |
| Income Before Tax | -255.07% | 21.87% | -1.30% | 58.62% | 94.36% |
| Income Tax Expenses | -257.78% | -97.12% | -- | 29.41% | -82.07% |
| Earnings from Continuing Operations | -234.46% | 25.13% | -0.49% | 58.39% | 94.20% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -234.46% | 25.13% | -0.49% | 58.39% | 94.20% |
| EBIT | -4.44% | -79.29% | -22.54% | -8.62% | 20.97% |
| EBITDA | -4.42% | -79.53% | -22.58% | -8.55% | 21.06% |
| EPS Basic | -244.44% | 25.00% | -1.05% | 58.64% | 94.34% |
| Normalized Basic EPS | -233.33% | 22.22% | -1.69% | 56.25% | 93.88% |
| EPS Diluted | -244.44% | 25.00% | -1.05% | 58.64% | 94.34% |
| Normalized Diluted EPS | -233.33% | 22.22% | -1.69% | 56.25% | 93.88% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.11% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.11% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
